Intravenous Line Phase-Wrap Artifact at Bilateral Axial 3-T Breast MRI: Identification, Analysis, and Solution.

Einat Slonimsky, Yusef Azraq, John M Gomori, Susan Fisch, Tal Arazi Kleinman, Tamar Sella

Abstract read

In one paragraph

Article in Radiology. Imaging cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Einat SlonimskyDepartment of Diagnostic Imaging, Department of Radiology, Penn State Health Milton S Hershey Medical Center, Penn State University Hospital, 500 University Dr, Hershey, PA 17033-0850 (E.S.); Department of Diagnostic Imaging, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Affiliated with the Hebrew University Medical School, Jerusalem, Israel (Y.A., J.M.G., S.F., T.S.); and Department of Diagnostic Imaging, Edith Wolfson Medical Center, Holon, Israel, Affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (T.A.K.).ORCID 0000-0001-8426-1555

Yusef AzraqDepartment of Diagnostic Imaging, Department of Radiology, Penn State Health Milton S Hershey Medical Center, Penn State University Hospital, 500 University Dr, Hershey, PA 17033-0850 (E.S.); Department of Diagnostic Imaging, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Affiliated with the Hebrew University Medical School, Jerusalem, Israel (Y.A., J.M.G., S.F., T.S.); and Department of Diagnostic Imaging, Edith Wolfson Medical Center, Holon, Israel, Affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (T.A.K.).

John M GomoriDepartment of Diagnostic Imaging, Department of Radiology, Penn State Health Milton S Hershey Medical Center, Penn State University Hospital, 500 University Dr, Hershey, PA 17033-0850 (E.S.); Department of Diagnostic Imaging, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Affiliated with the Hebrew University Medical School, Jerusalem, Israel (Y.A., J.M.G., S.F., T.S.); and Department of Diagnostic Imaging, Edith Wolfson Medical Center, Holon, Israel, Affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (T.A.K.).

Susan FischDepartment of Diagnostic Imaging, Department of Radiology, Penn State Health Milton S Hershey Medical Center, Penn State University Hospital, 500 University Dr, Hershey, PA 17033-0850 (E.S.); Department of Diagnostic Imaging, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Affiliated with the Hebrew University Medical School, Jerusalem, Israel (Y.A., J.M.G., S.F., T.S.); and Department of Diagnostic Imaging, Edith Wolfson Medical Center, Holon, Israel, Affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (T.A.K.).

Tal Arazi KleinmanDepartment of Diagnostic Imaging, Department of Radiology, Penn State Health Milton S Hershey Medical Center, Penn State University Hospital, 500 University Dr, Hershey, PA 17033-0850 (E.S.); Department of Diagnostic Imaging, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Affiliated with the Hebrew University Medical School, Jerusalem, Israel (Y.A., J.M.G., S.F., T.S.); and Department of Diagnostic Imaging, Edith Wolfson Medical Center, Holon, Israel, Affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (T.A.K.).

Tamar SellaDepartment of Diagnostic Imaging, Department of Radiology, Penn State Health Milton S Hershey Medical Center, Penn State University Hospital, 500 University Dr, Hershey, PA 17033-0850 (E.S.); Department of Diagnostic Imaging, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Affiliated with the Hebrew University Medical School, Jerusalem, Israel (Y.A., J.M.G., S.F., T.S.); and Department of Diagnostic Imaging, Edith Wolfson Medical Center, Holon, Israel, Affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (T.A.K.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To understand and remove the source of a phase-wrap artifact produced by residual contrast agent in the intravenous line during acquisition of bilateral axial 3-T dynamic contrast material-enhanced (DCE) breast MRI. Materials and Methods: A two-part study involved a phantom experiment, followed by an institutional review board approved clinical intervention, to evaluate the phase-wrap artifact at MRI. A phantom model evaluated artifact production by using an intravenous line filled with fluids with varying concentrations of gadolinium-based contrast agent (0, 0.4, 0.8, 1.2, 1.6, and 2 mmol/mL) and by positioning the simulated intravenous line within several fields of view (FOV) at 3-T MRI in breast coils. Next, a clinical assessment was performed with a total of 400 patients (control group:interventional group, 200:200) to determine the effect of taping the intravenous line to the patients' backs. Breast MR images were assessed blindly for the presence of the artifact. Software was used for statistical analysis with a Results: In the phantom model, the artifact was produced only with a 0.4 mmol/mL gadolinium concentration and when the tubing was either close to the edge or within a FOV of 350-450 mm. In the clinical experiment, the artifact was more prevalent in the retrospective control group than in the prospective intervention group (52.5% [105 of 200] vs 22% [44 of 200]; Conclusion: The presence of phase-wrap artifacts can be reduced by moving the contrast agent intravenous line out of the FOV during acquisition by taping it to a patient's back during bilateral axial 3-T DCE breast MRI.

Indexed as

ArtifactsMagnetic Resonance ImagingBreastContrast MediaFemaleHumansProspective StudiesRetrospective StudiesContrast Media

Identifiers

PMID33778747

DOI10.1148/rycan.2020200004

PMCPMC7983766

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.